Molecular docking, synthesis and biological evaluation of Vascular Endothelial Growth Factor (VEGF) B based peptide as antiangiogenic agent targeting the second domain of the Vascular Endothelial Growth Factor Receptor 1 (VEGFR1D2) for anticancer application

Signal Transduct Target Ther. 2020 Jun 5;5(1):76. doi: 10.1038/s41392-020-0177-z.
No abstract available

Publication types

  • Letter

MeSH terms

  • Angiogenesis Inhibitors / chemistry
  • Humans
  • Molecular Docking Simulation
  • Neovascularization, Pathologic / genetics*
  • Neovascularization, Pathologic / pathology
  • Peptides / chemistry
  • Peptides / genetics
  • Vascular Endothelial Growth Factor A / genetics*
  • Vascular Endothelial Growth Factor A / ultrastructure
  • Vascular Endothelial Growth Factor B / genetics*
  • Vascular Endothelial Growth Factor B / ultrastructure
  • Vascular Endothelial Growth Factor Receptor-1 / genetics*
  • Vascular Endothelial Growth Factor Receptor-1 / ultrastructure

Substances

  • Angiogenesis Inhibitors
  • Peptides
  • VEGFA protein, human
  • VEGFB protein, human
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factor B
  • Vascular Endothelial Growth Factor Receptor-1